Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 531

1.

Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.

Bouchet S, Poulette S, Titier K, Moore N, Lassalle R, Abouelfath A, Italiano A, Chevreau C, Bompas E, Collard O, Duffaud F, Rios M, Cupissol D, Adenis A, Ray-Coquard I, Bouché O, Le Cesne A, Bui B, Blay JY, Molimard M.

Eur J Cancer. 2016 Feb 3;57:31-38. doi: 10.1016/j.ejca.2015.12.029. [Epub ahead of print]

PMID:
26851399
2.

[2015 through the eyes of the Bulletin of Cancer editorial board].

Magné N, Massard C, Bay JO, André T, Blay JY, Goncalves A, Orbach D, Wislez M, Thariat J, Penel N, Rancoule C, Vignot S.

Bull Cancer. 2016 Jan;103(1):3-17. doi: 10.1016/j.bulcan.2015.11.006. Epub 2016 Jan 15. Review. French.

PMID:
26782079
3.

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.

Reichardt P, Demetri GD, Gelderblom H, Rutkowski P, Im SA, Gupta S, Kang YK, Schöffski P, Schuette J, Soulières D, Blay JY, Goldstein D, Fly K, Huang X, Corsaro M, Lechuga MJ, Martini JF, Heinrich MC.

BMC Cancer. 2016 Jan 15;16(1):22. doi: 10.1186/s12885-016-2051-5.

4.

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.

Patrikidou A, Domont J, Chabaud S, Ray-Coquard I, Coindre JM, Bui-Nguyen B, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Pérol D, Emile JF, Blay JY, Le Cesne A; French Sarcoma Group.

Eur J Cancer. 2016 Jan;52:173-80. doi: 10.1016/j.ejca.2015.10.069. Epub 2015 Dec 11.

PMID:
26687836
5.

Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.

Maillet D, Gan HK, Blay JY, You B, Péron J.

Eur J Cancer. 2016 Jan;52:26-32. doi: 10.1016/j.ejca.2015.08.025. Epub 2015 Nov 27.

PMID:
26630531
6.

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.

Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcberg JR, Litière S, Blay JY.

J Clin Oncol. 2015 Dec 20;33(36):4276-83. doi: 10.1200/JCO.2015.62.4304. Epub 2015 Nov 16.

PMID:
26573069
7.

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).

Penel-Page M, Ray-Coquard I, Larcade J, Girodet M, Bouclier L, Rogasik M, Corradini N, Entz-Werle N, Brugieres L, Domont J, Lervat C, Piperno-Neumann S, Pacquement H, Bay JO, Gentet JC, Thyss A, Chaigneau L, Narciso B, Cornille H, Blay JY, Marec-Bérard P.

BMC Cancer. 2015 Nov 5;15:854. doi: 10.1186/s12885-015-1894-5.

8.

Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I.

Nishida T, Tsujimoto M, Takahashi T, Hirota S, Blay JY, Wataya-Kaneda M.

J Gastroenterol. 2015 Oct 29. [Epub ahead of print]

PMID:
26511941
9.

KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome.

Brahmi M, Alberti L, Dufresne A, Ray-Coquard I, Cassier P, Meeus P, Decouvelaere AV, Ranchère-Vince D, Blay JY.

BMC Cancer. 2015 Oct 24;15:780. doi: 10.1186/s12885-015-1817-5.

10.

The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members.

Maillet D, Blay JY, You B, Rachdi A, Gan HK, Péron J.

Ann Oncol. 2016 Jan;27(1):192-8. doi: 10.1093/annonc/mdv485. Epub 2015 Oct 19.

PMID:
26483049
11.

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.

Khalifa J, Ouali M, Chaltiel L, Le Guellec S, Le Cesne A, Blay JY, Cousin P, Chaigneau L, Bompas E, Piperno-Neumann S, Bui-Nguyen B, Rios M, Delord JP, Penel N, Chevreau C.

BMC Cancer. 2015 Oct 15;15:700. doi: 10.1186/s12885-015-1697-8.

12.

Adjuvant imatinib treatment in gastrointestinal stromal tumor: which risk stratification criteria and for how long? A case report.

Blay JY, Levard A.

Anticancer Drugs. 2016 Jan;27(1):71-5. doi: 10.1097/CAD.0000000000000286.

PMID:
26457546
13.

Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.

Brahmi M, Thiesse P, Ranchere D, Mognetti T, Pinson S, Renard C, Decouvelaere AV, Blay JY, Combemale P.

PLoS One. 2015 Oct 7;10(10):e0138386. doi: 10.1371/journal.pone.0138386. eCollection 2015.

14.

Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.

Pivot X, Aulagner G, Blay JY, Fumoleau P, Kaliski A, Sarkozy F, Limat S.

Anticancer Drugs. 2015 Nov;26(10):1009-16. doi: 10.1097/CAD.0000000000000287. Review.

PMID:
26352219
15.

SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.

Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, Auguste A, Pissaloux D, Boyault S, Paindavoine S, Dechelotte PJ, Besse B, Vignaud JM, Brevet M, Fadel E, Richer W, Treilleux I, Masliah-Planchon J, Devouassoux-Shisheboran M, Zalcman G, Allory Y, Bourdeaut F, Thivolet-Bejui F, Ranchere-Vince D, Girard N, Lantuejoul S, Galateau-Sallé F, Coindre JM, Leary A, Delattre O, Blay JY, Tirode F.

Nat Genet. 2015 Oct;47(10):1200-5. doi: 10.1038/ng.3399. Epub 2015 Sep 7.

PMID:
26343384
16.

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.

Jiang X, Pissaloux D, De La Fouchardiere C, Desseigne F, Wang Q, Attignon V, Fondrevelle ME, De La Fouchardiere A, Perol M, Cassier P, Seigne C, Perol D, Ray-Coquard I, Meeus P, Fayette J, Flechon A, Le Cesne A, Penel N, Tredan O, Blay JY.

Oncotarget. 2015 Sep 22;6(28):26388-99. doi: 10.18632/oncotarget.4557.

17.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J.

N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.

PMID:
26287849
18.

The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.

Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK.

Gastric Cancer. 2016 Jan;19(1):3-14. doi: 10.1007/s10120-015-0526-8. Epub 2015 Aug 15.

19.

The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.

Barrios CH, Blackstein ME, Blay JY, Casali PG, Chacon M, Gu J, Kang YK, Nishida T, Purkayastha D, Woodman RC, Reichardt P.

Eur J Cancer. 2015 Nov;51(16):2423-33. doi: 10.1016/j.ejca.2015.07.010. Epub 2015 Aug 3.

20.

Small cell carcinoma of the ovary, hypercalcemic type/ ovarian malignant rhabdoid tumor: report of a bilateral case in a teenager associated with SMARCA4 germline mutation.

Lavrut PM, LE Loarer F, Normand C, Grosos C, Dubois R, Buenerd A, Conter C, Dijoud F, Blay JY, Collardeau-Frachon S.

Pediatr Dev Pathol. 2015 Jul 31. [Epub ahead of print]

PMID:
26230154
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk